Aakash Desai: MYC IHC could be crucial in tailoring immunotherapy approaches in NSCLC

Aakash Desai, Assistant Professor at O’Neal Comprehensive Cancer Center at UAB, shared a post on LinkedIn:

“Monday Read out in the Lung Cancer Journal ESMO- European Society for Medical Oncology.

Our recent publication explores the “Predictive value of MYC IHC in NSCLC with IO.

 Key Insights:
➡ Positive MYC IHC is a promising marker for predicting overall survival (OS) following immuno therapy.

➡ Cases with MYC positive and PD-L1 negative status exhibit notably shorter OS, spotlighting a critical subgroup for potential therapeutic focus.

Our study suggests that MYC IHC, more than MYC copy number gain, could be crucial in tailoring immunotherapy approaches, possibly enhancing patient outcomes in non-small cell lung cancer (NSCLC).

More prospective studies are needed in this space to outline MYC’s role as a true biomarker of immuno therapy in NSCLC.

Full study details here.”

Predictive value and molecular correlates of MYC immunohistochemistry and copy number gain in non-small cell lung carcinomas treated with immunotherapy

Authors: Julia Naso, Aakash Desai, Caleb J. Smith, Yash P. Ashara , Stephen Yip, and Ying-Chun Lo.

Source: Aakash Desai/LinkedIn